POTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's diseas ...
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process ...
Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging ...
Spartanburg County continues to set the bar in South Carolina, and in many ways, across the Southeast, when it comes to economic investment and job creation.” — OneSpartanburg, Inc. President and CEO ...
Vladimir Putin took part in the plenary session of the Future Technologies Forum. The discussion theme is Bioeconomy for ...
New workflow validated on Dynamic Devices Lynx® delivers scalable plasmid DNA extraction from Midi to Maxi-prep volumes ...
A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...
Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - - Advancement reflects continued execution of ...
The International Association of Top Professionals (IAOTP) will honor Dr. Kerriann Greenhalgh at their annual awards ...
2d
SolasCure Completes Phase II Clinical Trial, Demonstrating Accelerated Healing With Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the successful completion of its second Phase II clinical trial, ...
Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...
Advances in organ and computer models are raising the prospect that some animal experiments could be eliminated. But there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results